Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Meta-analysis
100%
Randomized Trial
100%
Trastuzumab
100%
HER2-positive Breast Cancer
100%
Chemotherapy
66%
Breast Cancer Recurrence
66%
Breast Cancer
33%
Patient Characteristics
33%
Tumor Characteristics
33%
Rate Ratio
33%
All-cause Mortality
33%
Recurrence Risk
33%
Chemotherapy Alone
33%
Breast Cancer Mortality
33%
Cancer Research
16%
High Risk
16%
Baseline Characteristics
16%
Tumor
16%
Local Recurrence
16%
Recurrence Rate
16%
Event Rate
16%
Extracellular Domain
16%
Treatment Duration
16%
Risk of Death
16%
Cardiac Toxicity
16%
Cancer Causes
16%
Breast Cancer Risk
16%
Long-term Benefit
16%
Inclusion Criteria
16%
Intention-to-treat
16%
ER Status
16%
Nodal Status
16%
Absolute Reductions
16%
Long-run Risk
16%
Node-negative
16%
Rank Analysis
16%
Node-positive
16%
Individual Patient Data
16%
Individual Patient Data Meta-analysis
16%
Cause-specific Mortality
16%
Adjuvant Trastuzumab
16%
Operable Breast Cancer
16%
HER2 mutation
16%
Underlying Cause of Death
16%
Second Primary Cancer
16%
Medical Research Council
16%
Estrogen Receptor (ER) Status
16%
Medicine and Dentistry
Meta-Analysis
100%
Breast Cancer
100%
Trastuzumab
100%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
100%
Recurrent Disease
88%
Tumor
33%
Recurrence Risk
22%
Cancer Mortality
22%
All Cause Mortality
22%
Diseases
11%
Estrogen Receptor
11%
Epidermal Growth Factor Receptor 2
11%
Second Cancer
11%
Intention-to-Treat Analysis
11%
Treatment Duration
11%
Cancer Research
11%
Patient-Data
11%
Medical Research
11%
Cardiotoxicity
11%
Primary Outcome
11%
Specific Mortality
11%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Trastuzumab
100%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
100%
Recurrent Disease
88%
Chemotherapy
66%
Recurrence Risk
22%
All Cause Mortality
22%
Cancer Mortality
22%
Diseases
11%
Malignant Neoplasm
11%
Estrogen Receptor
11%
Cardiotoxicity
11%
Second Cancer
11%
Epidermal Growth Factor Receptor 2
11%
Biochemistry, Genetics and Molecular Biology
Trastuzumab
100%
All Cause Mortality
28%
Cancer Mortality
28%
Estrogen Receptor
14%
Patient Coding
14%
Immunology and Microbiology
Trastuzumab
100%
All Cause Mortality
28%
Cancer Mortality
28%
Patient Coding
14%